Non-invasive diagnosis of endometriosis and moderate-severe endometriosis with serum CA125, endocan, YKL-40, and copeptin quadruple panel

Onur Güralp, Barış Kaya, Baris Kaya, Nevin Tüten, Tüten N, Mine Kucur, Kucur M, Mine Kücür, Eduard Malik, Abdullah Tüten, Tüten A
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2020 · vol. 41(6) , pp. 927–932 · doi:10.1080/01443615.2020.1803245 · PMID:33064040 · W3092923023
article OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-28 ⓘ

A quadruple panel of serum markers (CA125, endocan, YKL-40, and copeptin) demonstrated high diagnostic accuracy for predicting endometriosis, particularly moderate-to-severe stages.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Considering the complex pathogenesis of endometriosis, which is associated with many cellular or molecular processes, such as proliferation, angiogenesis, inflammation, we evaluated the diagnostic value of a quadruple panel of serum markers CA125, endocan, YKL-40 and copeptin, for the prediction of endometriosis and moderate – severe endometriosis. Seventy women with endometriosis and 70 women without endometriosis were evaluated. Serum CA125, endocan, copeptin and YKL-40 levels were significantly increased in women with endometriosis compared to the women without endometriosis and in the minimal – mild endometriosis group compared to the no-endometriosis group. YKL-40, endocan and copeptin levels were significantly increased in the moderate – severe endometriosis group compared to the mild –moderate endometriosis group but the difference in CA125 levels remained non-significant. The quadruple panel score had an AUC of 0.954, a sensitivity of 96.5% and specificity of 84.6% for prediction of moderate – severe endometriosis. Zero or one positive marker had a sensitivity of 91.4% and specificity of 88.57% to rule out endometriosis. In conclusion, a quadruple panel of serum markers-CA125, endocan, YKL-40, and copeptin may be beneficial for the diagnosis of endometriosis and especially moderate – severe endometriosis. Further studies are needed to prove the efficacy of this panel.Impact statementWhat is already known on this subject? Many serum markers including CA125 have been investigated so far and suggested to be associated with endometriosis. However, none of these markers is sensitive and specific enough to diagnose endometriosis.What do the results of this study add? A quadruple panel score (CA125, endocan, YKL-4 and copeptin) had an AUC of 0.954, a sensitivity of 96.5% and specificity of 84.6% for prediction of moderate – severe endometriosis.What are the implications of these findings for clinical practice and/or further research? A high score may be beneficial to warn the surgeon about the risk of moderate to severe endometriosis if the patient will be operated anyway. A negative test of the quadruple panel may show high odds that there is no endometriosis which may prevent unnecessary surgery.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

CA-125 Antigen Chitinase-3-Like Protein 1 Endometriosis Glycopeptides Hematologic Tests Membrane Proteins Neoplasm Proteins Proteoglycans Adolescent Adult Area Under Curve Biological Specimen Banks Biomarkers Biomarkers CA-125 Antigen Chitinase-3-Like Protein 1 Endometriosis Female Glycopeptides Hematologic Tests

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (16)

Cited by (9)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:36.268089+00:00
unpaywall
last seen: 2026-06-05T02:00:03.366016+00:00
License: CC0 · commercial use OK